# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple scleros...
– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product P...
HC Wainwright & Co. analyst Mitchell Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and lowers the p...
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate o...
JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target fro...